WuXi XDC Cayman Inc (2268) Fair Value & Analysis
Healthcare · HK · Market cap HK$74.1B
Fair value as of: Aug 13, 2026
From 26 valuation models · updated today
Fair value updated Aug 13, 2026, revised from HK$21.42 to HK$19.46 (−9.2%) since Aug 5, 2026. Share price +8.3% over the past month.
A solid business, but screening 69% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (HK$32.36). The favourable scenario is already priced in.
- The model range is unusually wide (HK$12.34 to HK$32.36). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (3 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
33‑month range HK$12.98 – HK$85.10 · fair‑value band HK$12.34 – HK$32.36 · the HK$63.35 price screens above the HK$19.46 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
WuXi XDC Cayman Inc (2268) currently trades at HK$63.35, while our model-based Fair Value estimate is HK$19.46, implying the stock looks roughly 69.3% overvalued today. The Quality Score stands at 52/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, WuXi XDC Cayman Inc generated revenue of HK$5.9B at a net margin of 24.9%. Revenue grew 35.9% year over year. It earns a return on equity of 17.1%. The balance sheet holds a net cash position of HK$632M. Fundamentals as of Aug 13, 2026
Our scenario range runs from HK$12.34 (bear case) to HK$32.36 (bull case); at HK$63.35, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat. The share trades about 26% below its 52-week high and 49% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -50% fair-value upside, at -69%, 2268 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings (HK$50.58) versus Dividend Discount (HK$1.39). Highest evidence: Growth DCF (80).
Notify me when 2268 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 53 · Market factors (momentum, volatility) 51
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally.
Full company description
WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It also provides international sales contracting services. Additionally, the company engages in the research and development, manufacturing, and marketing of anti-tumor drugs. WuXi XDC Cayman Inc. has a strategic collaboration with Earendil Labs; and Akari Therapeutics. The company was founded in 2013 and is headquartered in Wuxi, China. WuXi XDC Cayman Inc. is a subsidiary of WuXi Biologics (Cayman) Inc. WuXi XDC Cayman Inc. operates as a subsidiary of WuXi Biologics (Cayman) Inc.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
WuXi XDC Cayman Inc reported revenue of HK$5.9B in FY2025 versus HK$311M in FY2021, a compound +109.1%/yr. Reported net income was HK$1.5B in FY2025, compounding +127.9%/yr from FY2021.
2268 screens 69% overvalued. Compare with Thermo Fisher Scientific Inc →
Earlier news
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.
- WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility
- Stronger Together, Shaping the Future | WuXi XDC and BioDlink Successfully Concluded 2026 Open Day
Peer Group
Diagnostics & Research · 135 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Diagnostics & Research median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $603.01 | $308.19 | -49% |
| Danaher Corporation DHR | $205.79 | $103.88 | -50% |
| WuXi AppTec Co 2359 | HK$198.90 | HK$157.39 | -21% |
| Lonza Group LONN | CHF 566.20 | CHF 259.80 | -54% |
| IDEXX Laboratories, Inc IDXX | $570.58 | $255.77 | -55% |
| Agilent Technologies, Inc A | $148.24 | $61.53 | -58% |
| Waters Corporation WAT | $416.15 | $121.96 | -71% |
| IQVIA Holdings IQV | $243.84 | $132.17 | -46% |
| Illumina, Inc ILMN | $192.91 | $95.51 | -50% |
| Mettler-Toledo International Inc MTD | $1,437 | $615.78 | -57% |
Compare WuXi XDC Cayman Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is WuXi XDC Cayman Inc (2268) overvalued or undervalued?
What is the fair value of 2268?
What is the quality score of 2268?
What is the revenue of WuXi XDC Cayman Inc (2268)?
What is the net profit margin of 2268?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track WuXi XDC Cayman Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.